Objective: The purpose of this investigation was to evaluate the use of systemically administered metronidazole during periodontal treatment, regarding its side effects. Method: Fifty-four subjects (mean age 46.4 ± 8), with chronic periodontitis (8 sites with probing depth >5mm) were selected. Plaque accumulation (0/1), bleeding on probing (0/1), probing pocket depth and clinical attachment level were monitored prior to therapy and 90 days post-therapy. After receiving full mouth scaling and root planing subjects were randomly assigned to a test (T, n=27) and a control group (C, n=27). Subjects in the test group received 400mg of systemically administered metronidazole 3 times/day, for 10 days. The control group received placebo. In order to evaluate possible side effects of metronidazole, a questionnaire of 13 items was applied at the end of the drug/placebo administration. Result:There were no significant differences between groups for clinical parameters at baseline (Mann-Whitney test). 67% of subjects in the test group and 33,3% in the control group reported some physical impact as discomfort, nausea, diarrhea, metallic taste, migraine or drowsiness (p<0.05, X² test). Considering the side effects separately, metallic taste (T=85% and C=12.5%) and lack of energy (T=100% and C=0%) have shown statistically significant differences for the impacts (p<0.05, X² test). Conclusion:These results suggest that ingestion of metronidazole at the dosage here described causes side effects, the most noticeable ones being metallic taste and lack of energy.

Back to the Periodontal Research - Therapy Program
Back to the IADR/AADR/CADR 80th General Session (March 6-9, 2002)

Top Level Search